Ozempic (semaglutide SC once-weekly) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 12 Diseases   138 Trials   138 Trials   3994 News 


«12...1617181920212223242526...3940»
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Biomarker, Enrollment open:  PORT: Pharmacogenetics of Response to GLP1R Agonists (clinicaltrials.gov) -  Aug 2, 2022   
    P1,  N=600, Recruiting, 
    Clinical improvements were obtained even in switchers, especially in those switching to semaglutide. Not yet recruiting --> Recruiting
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk, Mounjaro (tirzepatide) / Eli Lilly
    Efficacy and Safety of Tirzepatide Versus Semaglutide in a Hispanic or Latino Population: A Prespecified Subgroup Analysis of SURPASS-2 (In Person and Livestreamed A315-316) -  Jul 16, 2022 - Abstract #ENDO2022ENDO_2434;    
    Learning Objective 1: After reading this abstract and viewing the associated presentation/poster, participants will be able to summarise efficacy and safety results for the GIP/GLP-1 receptor agonist tirzepatide in the Hispanic or Latino population of the SURPASS-2 study and compare the findings with semaglutide 1 mg Science Topic(s) for Diabetes and Glucose Metabolism: Diabetes Clinical Care Abstract Body: Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrated clinically meaningful reductions in HbA1c and body weight that were significantly greater compared with semaglutide in patients with type 2 diabetes on background metformin...The most common adverse events were gastrointestinal in the tirzepatide and semaglutide arms, including nausea (Hispanic or Latino 11-17% and 13%; non-Hispanic or Latino 32-36% and 29%), diarrhoea (10-13% and 10%; 15-24% and 17%) and vomiting (4-7% and 7%; 10-16% and 12%). Consistent with the primary SURPASS-2 results, in a Hispanic or Latino population with type 2 diabetes, tirzepatide demonstrated greater reductions from baseline in HbA1c and body weight than the selective GLP-1 receptor agonist semaglutide, with a comparable safety profile.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    PK/PD data, Journal:  Population pharmacokinetic of paracetamol and atorvastatin with co-administration of semaglutide. (Pubmed Central) -  Jul 16, 2022   
    Semaglutide affected pharmacokinetic model parameters of paracetamol and atorvastatin, and minor quantitative differences in gastric emptying between placebo vs. semaglutide administration were observed. However, these effects of semaglutide were considered not to be of clinical relevance.
  • ||||||||||  Mounjaro (tirzepatide) / Eli Lilly
    Journal:  Tirzepatide (Mounjaro) for type 2 diabetes. (Pubmed Central) -  Jul 16, 2022   
    However, these effects of semaglutide were considered not to be of clinical relevance. No abstract available
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Review, Journal:  Once-Weekly Semaglutide for Weight Management: A Clinical Review. (Pubmed Central) -  Jul 15, 2022   
    It is a feasible option for chronic weight management, with data for up to 2 years. It is currently the only once-weekly weight loss medication, although cost may limit its utilization.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Journal:  Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. (Pubmed Central) -  Jul 10, 2022   
    P3
    One year after withdrawal of once-weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two-thirds of their prior weight loss, with similar changes in cardiometabolic variables. Findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health.
  • ||||||||||  Mounjaro (tirzepatide) / Eli Lilly
    Tirzepatide-induced weight loss in type 2 diabetes is independent of nausea, vomiting, or diarrhoea (Short Oral Discussion Area) -  Jul 9, 2022 - Abstract #EASD2022EASD_1071;    
    P3
    Findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health. Superior weight loss with TZP appears to be independent of reported nausea, vomiting, or diarrhoea AEs across the SURPASS 1-5 clinical trials.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Semaglutide 2.4 mg improved glucose metabolism and reverted prediabetes to normoglycaemia in adults with overweight or obesity vs liraglutide 3.0 mg (STEP 8) (Short Oral Discussion Area) -  Jul 9, 2022 - Abstract #EASD2022EASD_1066;    
    P3
    The most frequent adverse events were gastrointestinal -related events that were mild to moderate in severity and occurred during the dose-escalation period. Both semaglutide 2.4 mg and liraglutide 3.0 mg had clinically beneficial effects on glucose metabolism and glycaemic status in participants with overweight/obesity and prediabetes, though the effect of semaglutide 2.4 mg was greater vs liraglutide 3.0 mg with approximately 25% more participants with prediabetes reverting to normoglycaemia.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Semaglutide 2.4 mg reduces the 10-year type 2 diabetes risk in people with overweight or obesity (Short Oral Discussion Area) -  Jul 9, 2022 - Abstract #EASD2022EASD_1065;    
    P3
    In summary, treatment with semaglutide 2.4 mg reduces the 10-year risk of T2D by ~60% regardless of initial glycaemic status, with sustained treatment required to maintain this benefit. These data suggest semaglutide 2.4 mg could help prevent T2D in people with obesity.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Reduced risk of kidney function loss in patients with type 2 diabetes treated with GLP-1 receptor agonists versus basal insulin (Short Oral Discussion Area) -  Jul 9, 2022 - Abstract #EASD2022EASD_1005;    
    The findings suggest that continuous use of GLP-1 RA may be associated with improved kidney outcomes, including a lower risk for kidney function loss, among patients with type 2 diabetes and preserved baseline kidney function. The ongoing FLOW trial will directly determine whether the GLP-1 RA once-weekly subcutaneous semaglutide reduces the risk of kidney disease progression in people with T2D and CKD.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Associations between weight loss and glycaemic control with once-weekly semaglutide 1.0 mg and 2.4 mg in the STEP 2 trial (Short Oral Discussion Area) -  Jul 9, 2022 - Abstract #EASD2022EASD_821;    
    P3
    In people with overweight/obesity and T2D, greater weight loss was associated with a greater chance of achieving HbA 1c <5.7% at both 20 and 68 weeks, with further benefits seen at the latter time point. Greater reductions in body weight were associated with higher proportions of participants achieving HbA 1c thresholds of <5.7%, <6.5% and <7.0% across all treatment groups.
  • ||||||||||  Mounjaro (tirzepatide) / Eli Lilly
    Effect of tirzepatide on fasting lipids in patients with type 2 diabetes: meta-analysis of randomised controlled trials (Bernard Hall) -  Jul 9, 2022 - Abstract #EASD2022EASD_437;    
    Based on pooled data from RCTs, treatment with tirzepatide dose-dependently decreased levels of triglycerides, T-C, LDL-C and VLDL-C versus placebo. As such, in addition to its glucose lowering effect, tirzepatide could be used to improve the atherogenic lipoprotein profile in patients with type 2 diabetes by complementing the effect of lipid lowering drugs.